Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference

Rhea-AI Summary

Belite Bio (NASDAQ: BLTE) announced that its executive management team will present at the Deutsche Bank ADR Virtual Investor Conference on November 4, 2025 at 10:30 AM ET. The presentation will be webcast and accessible via the conference site at www.adr.db.com/dbvic. A replay will be available for 90 days after the presentation.

The presentation covers corporate strategy and clinical-stage programs focused on degenerative retinal diseases; investors can access the live webcast and on-demand replay through the conference platform.

News Market Reaction – BLTE

+5.35% 2.0x vol

1 alert

+5.35% News Effect

+$164M Valuation Impact

$3.22B Market Cap

2.0x Rel. Volume

On the day this news was published, BLTE gained 5.35%, reflecting a notable positive market reaction. This price movement added approximately $164M to the company's valuation, bringing the market cap to $3.22B at that time. Trading volume was elevated at 2.0x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will present at the Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference hosted by VirtualInvestorConferences.com, on November 4, 2025. Details of the presentation are as follows:

• 10:30 am ET, corporate presentation
  

Webcast Link Instructions
A webcast of the presentation will be available on the conference website at www.adr.db.com/dbvic. The replay will be accessible for 90 days following the presentation date.

About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as STGD1 and GA in advanced dry AMD, in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at www.belitebio.com.

Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com

Julie Fallon
belite@argotpartners.com

FAQ

When will Belite Bio (BLTE) present at the Deutsche Bank ADR Virtual Investor Conference?

Belite Bio (BLTE) will present on November 4, 2025 at 10:30 AM ET.

How can investors watch Belite Bio's (BLTE) November 4, 2025 presentation?

The presentation will be webcast on the conference site at www.adr.db.com/dbvic.

Will there be a replay of Belite Bio's (BLTE) Deutsche Bank ADR conference presentation?

Yes. A replay will be available for 90 days following the November 4, 2025 presentation.

What topics will Belite Bio (BLTE) cover at the November 4, 2025 conference?

The executive team will present corporate updates and progress on its clinical-stage programs for degenerative retinal diseases.

Is registration required to view the Belite Bio (BLTE) webcast at the Deutsche Bank ADR conference?

Access is provided via the conference website; attendees should follow the site instructions at www.adr.db.com/dbvic for viewing details.